These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28656940)

  • 1. Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.
    Messori A
    Sci Pharm; 2016 Jan; 84(4):618-624. PubMed ID: 28656940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship.
    Messori A
    Sci Pharm; 2016; 84(1):73-9. PubMed ID: 27110499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
    Kawakami A; Masamune K
    Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of early phase price agreements on prices of orphan drugs.
    Nuijten M; Van Wilder P
    BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing a reasonable price for an orphan drug.
    Berdud M; Drummond M; Towse A
    Cost Eff Resour Alloc; 2020; 18():31. PubMed ID: 32908456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.
    Medic G; Korchagina D; Young KE; Toumi M; Postma MJ; Wille M; Hemels M
    J Mark Access Health Policy; 2017; 5(1):1299665. PubMed ID: 28473888
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparative study of orphan drug prices in Europe.
    Young KE; Soussi I; Hemels M; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1297886. PubMed ID: 28473887
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019.
    Villa F; Di Filippo A; Pierantozzi A; Genazzani A; Addis A; Trifirò G; Cangini A; Tafuri G; Settesoldi D; Trotta F
    Front Med (Lausanne); 2022; 9():820757. PubMed ID: 35252257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement.
    Eichler HG; Kossmeier M; Zeitlinger M; Schwarzer-Daum B
    Front Pharmacol; 2023; 14():1074512. PubMed ID: 36778019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saving orphan drug legislations: misconceptions and clarifications.
    Hyry HI; Cox TM; Roos JC
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):111-7. PubMed ID: 26768506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
    Shajarizadeh A; Hollis A
    Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems.
    Pauly MV
    Value Health; 2017 Feb; 20(2):278-282. PubMed ID: 28237209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.